Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck

• DOI: 10.1007/bf00874161
• Publication Date: 2004-12-27T23:59:35Z
• Authors: Sarah A. Taylor; Jacqueline Benedetti; David Schuller; Stephen P. Richman; Goronwy O. Broun; Alexander Hantel
• Keywords: Metastatic carcinoma

Twenty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with piroxantrone 150 mg/m2 intravenously every 21 days. There were no objective responses. The 95% upper confidence bound for response is 15%. Primary toxicity was hematologic.